Work

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.3991.3991

Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L Bartlett, Tanya Siddiqi, Julio C. Chavez, Chitra M. Hosing, Armin Ghobadi, Lihua E. Budde, Lynn Navale, Jeff S. Aycock, Jeff Wiezorek, William Y. Go

Institutions: Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, City Of Hope National Medical Center, Kite Pharma (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2469842243

FWCI: 1.043

Cites:

Cited by: 9

Related to: 10